GSK said it is making its largest manufacturing investment in the US yet, allocating $800 million to upgrade its vaccine production site in Pennsylvania. … ...
GSK has made its largest-ever single manufacturing investment in the US. Image credit: Shutterstock/ Golden Shrimp. Following outlays for sites in the UK and Belgium earlier this year, GSK is planning ...
THE ARM FOR THE LANCASTER COUNTY ECONOMY. THIS IS FOR GSK, THE LARGEST INVESTMENT IN MANUFACTURING WE’VE EVER DONE IN THE UNITED STATES. THE $800 MILLION WILL BE USED TO EXPAND GSK’S MARIETTA ...
During a press conference earlier today, GSK officials, alongside Governor Josh Shapiro and Department of Community and Economic Development (DCED) Secretary Rick Siger, announced the investment ...
After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...
Preliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy has potential in younger adults with certain risk factors, potentially positioning the shot ...
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...
Unknown litigation costs have cast a cloud over wide-moat GSK GSK since 2020, when the US Food and Drug Administration requested that Zantac be taken off the market. But earlier this month ...
The market expects GSK (GSK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook is ...
GSK is pumping 50 million pounds sterling (about $65 million) into a five-year collaboration with the University of Cambridge and Cambridge University Hospitals to more precisely treat immune ...
This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.
GSK has announced a £50m ($54.3m) investment in a new partnership with the University of Cambridge and Cambridge University Hospitals to expedite immune-related disease research and development (R&D).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback